The respiratory syncytial virus vaccines are here: Implications for solid organ transplantation.
Am J Transplant
; 24(6): 897-904, 2024 Jun.
Article
in En
| MEDLINE
| ID: mdl-38341028
ABSTRACT
In 2023, the Food and Drug Administration approved 2 recombinant subunit respiratory syncytial virus (RSV) vaccines based on prefusion RSV F glycoproteins for the prevention of RSV-associated lower respiratory tract disease. These vaccines were subsequently recommended for individuals ≥60 years of age using shared clinical decision-making by the Center for Disease Control and Prevention's Advisory Committee on Immunization Practices. The development, deployment, and uptake of respiratory virus vaccines are of particular importance for solid organ recipients who are at higher risk of infectious complications and poor clinical outcomes, including from RSV-associated lower respiratory tract disease, compared to patients without immunocompromise. This review aims to summarize what is currently known about the burden of RSV disease in solid organ transplantation, to describe the currently available tools to mitigate the risk, and to highlight considerations regarding the implementation of these vaccines before and after transplantation. We also explore areas of unmet need for organ transplant recipients including questions of RSV vaccine effectiveness and safety, inequities in disease and vaccine access based on race and socioeconomic status, and expansion of coverage to immunocompromised individuals below the age of 60 years.
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Organ Transplantation
/
Respiratory Syncytial Virus Infections
/
Respiratory Syncytial Virus Vaccines
Type of study:
Prognostic_studies
Limits:
Humans
Language:
En
Journal:
Am J Transplant
Journal subject:
TRANSPLANTE
Year:
2024
Document type:
Article
Affiliation country: